AI algorithm for detecting prostate cancer shows more than 98% sensitivity, 97% specificity in study - MedCity News

An Israeli startup developing a digital pathology system based around artificial intelligence has published what it calls "outstanding outcomes" in a clinical validation study. Tel Aviv-based Ibex Medical Analysis said Tuesday that it had published data on Galen Prostate, its AI-based system for use by pathologists to detect and measure prostate cancer, in The Lancet Digital Health. The company called it the first and only AI-based system used by pathologists in routine clinical practice. The study took place at the University of Pittsburgh Medical Center, led by Drs. According to the data, sensitivity measured for prostate cancer was 98.46%, and specificity was 97.33%, while the operating characteristic curve was 0.991.